Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Biogen Idec 3Q11 | Contract Pharma

What are you searching for?

Sign in
Breaking News

Financial Report: Biogen Idec 3Q11

Revenues up 11%

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec 3Q11
 

3Q Revenues: $1.3 billion (+11%)
 

3Q Earnings: $352 million (+38%)
 

YTD Revenues: $3.7 billion (+6%) 
 

YTD Earnings: $966.5 million (earnings were $626.8 million 3Q10)
 

Comments: Global in-market sales of Tysabri were $393 million in the quarter (+28%). Avonex sales increased 6% to $682 million. Rituxan revenues from the company’s joint business arrangement with Genentech were $266 million (+3%). Royalties were $52 million in the quarter, up 43%.

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters